NeoBiocon and Novartis partner together to offer anti-diabetes drug in UAE


NeoBiocon has partnered with Novartis to offer diabetes drug Vildagliptin in the United Arab Emirates. Vildagliptin is an oral anti-diabetic agent. NeoBiocon is one of the region’s top 25 pharma firms, and it is the number one generic pharma company in the UAE.

Read the source article at Business Standard

About the Author

Related Posts

Leave a Reply